Amersham

Global Microarray Market Report 2022-2028: Rising Use of Microarrays to Diagnose Infectious Diseases Fuels Growth - ResearchAndMarkets.com

Retrieved on: 
Friday, December 16, 2022
Health, Genetics, Geography, RNA, Agilent Technologies, Genetic testing, Diagnosis, Drug discovery, Prevalence, Government, Proteomics, DNA, Cancer, News, Prognosis, Gene expression, Conditional sentence, Microarray, Infection, Growth, Research, Amersham, Somatic mutation, Vaccine, Agriculture, Marketing

The global microarray market is anticipated to grow at a CAGR of around 7.8% during the forecast period.

Key Points: 
  • The global microarray market is anticipated to grow at a CAGR of around 7.8% during the forecast period.
  • Moreover, increasing prevalence of various chronic diseases and the rise of usage of microarrays technology for the diagnosis of such infectious diseases are also contributing to the growth of the microarray market.
  • On the basis of type, the market is segmented into DNA microarrays, protein microarray, peptide microarray, tissue microarray, and others (cellular microarray).
  • Among types, the DNA microarray segment is projected to have a significant share in the global microarray market.

Farid Fezoua joins TVM Capital Healthcare as Managing Partner

Retrieved on: 
Monday, July 5, 2021
Amersham, GE Healthcare, Magnetic resonance imaging, Radiopharmaceuticals, Health care

DUBAI, UAE, SINGAPORE, BOSTONand MUNICH, July 5, 2021 /PRNewswire/ -- TVM Capital Healthcare, a global specialist healthcare private equity firm operating in emerging markets, announced today that Farid Fezoua joins the firm as a Managing Partner.

Key Points: 
  • DUBAI, UAE, SINGAPORE, BOSTONand MUNICH, July 5, 2021 /PRNewswire/ -- TVM Capital Healthcare, a global specialist healthcare private equity firm operating in emerging markets, announced today that Farid Fezoua joins the firm as a Managing Partner.
  • Farid comes to TVM Capital Healthcare following the successful exit of Cambridge Medical and Rehabilitation Center (CMRC) in March 2021 for $232 million, which represented a 4.6x return on capital invested the largest MENA healthcare deal in recent years.
  • Farid Fezoua, Managing Partner, TVM Capital Healthcare, said: "There are countless opportunities for healthcare investments in both the MENA and Southeast Asia regions, so it is an exciting time to be joining a dedicated healthcare private equity investor.
  • Mr. Fezoua will also become Chairman of the Board at TVM Capital Healthcare's portfolio company, Manzil Healthcare Services, replacing the firm's Operating Partner, Carl Stanifer, who will focus on TVM Capital Healthcare's investment and company building plans in Southeast Asia.

Farid Fezoua joins TVM Capital Healthcare as Managing Partner

Retrieved on: 
Monday, July 5, 2021
Amersham, GE Healthcare, Magnetic resonance imaging, Radiopharmaceuticals, Health care

DUBAI, UAE, SINGAPORE, BOSTONand MUNICH, July 5, 2021 /PRNewswire/ -- TVM Capital Healthcare, a global specialist healthcare private equity firm operating in emerging markets, announced today that Farid Fezoua joins the firm as a Managing Partner.

Key Points: 
  • DUBAI, UAE, SINGAPORE, BOSTONand MUNICH, July 5, 2021 /PRNewswire/ -- TVM Capital Healthcare, a global specialist healthcare private equity firm operating in emerging markets, announced today that Farid Fezoua joins the firm as a Managing Partner.
  • Farid comes to TVM Capital Healthcare following the successful exit of Cambridge Medical and Rehabilitation Center (CMRC) in March 2021 for $232 million, which represented a 4.6x return on capital invested the largest MENA healthcare deal in recent years.
  • Farid Fezoua, Managing Partner, TVM Capital Healthcare, said: "There are countless opportunities for healthcare investments in both the MENA and Southeast Asia regions, so it is an exciting time to be joining a dedicated healthcare private equity investor.
  • Mr. Fezoua will also become Chairman of the Board at TVM Capital Healthcare's portfolio company, Manzil Healthcare Services, replacing the firm's Operating Partner, Carl Stanifer, who will focus on TVM Capital Healthcare's investment and company building plans in Southeast Asia.

GE Healthcare and the American College of Cardiology Join Forces to Advance AI in Cardiac Care

Retrieved on: 
Thursday, June 3, 2021
Hardware, Technology, Continuing, University, Radiology, Pharmaceutical, Education, Training, Medical devices, Other Technology, Cardiology, Science, Biotechnology, Health, Research, Companies, Amersham, GE Healthcare, Magnetic resonance imaging, Radiopharmaceuticals, Economy of the United States, Industry economics), General Electric, John S. Rumsfeld, GE Technology Infrastructure

GE Healthcare will lend its unique perspective as a leading global medical technology and digital solutions innovator in connected cardiovascular care to this forum.

Key Points: 
  • GE Healthcare will lend its unique perspective as a leading global medical technology and digital solutions innovator in connected cardiovascular care to this forum.
  • We are excited to have GE Healthcare join forces with the Applied Health Innovation Consortium, says John Rumsfeld, MD, PhD, FACC, ACC Chief Innovation Officer and Chief Science & Quality Officer.
  • In our mission to transform cardiovascular care and improve heart health, GE Healthcare is a great collaborator to help build a roadmap for AI and digital technology that bridges gaps in clinical care.
  • GE Healthcare is the $18 billion healthcare business of GE (NYSE: GE).

Investigation Report on China's Iodixanol Market, 2016-2020 & 2021-2025: Relevant Concepts, Sales, Major Manufacturers, Pricing & Prospects - ResearchAndMarkets.com

Retrieved on: 
Thursday, May 6, 2021
Health, Pharmaceutical, Radiocontrast agents, Medical imaging, Companies, Projectional radiography, Acetanilides, Benzamides, Iodixanol, Amersham, Buckinghamshire, Angiography, GE Healthcare, General Electric

b'The "Investigation Report on China\'s Iodixanol Market 2021-2025" report has been added to ResearchAndMarkets.com\'s offering.\nIodixanol is a third-generation contrast agent that has good solubility and is isotonic to plasma.

Key Points: 
  • b'The "Investigation Report on China\'s Iodixanol Market 2021-2025" report has been added to ResearchAndMarkets.com\'s offering.\nIodixanol is a third-generation contrast agent that has good solubility and is isotonic to plasma.
  • It is used for cardiovascular angiography, cerebrovascular angiography, abdominal angiography, and so on.
  • Iodixanol was developed by Nycomed, a Norwegian company, naming VISIPAQUE (Nycomed was acquired by GE after the merge with Amersham, and become GE Healthcare).\nIn 2001, Iodixanol entered the Chinese market.
  • Therefore, the number of equipment still has the potential to increase, which will lead the contrast agent market to expand.

First Nation Group to Offer GE Healthcare Medical Solutions to Help Improve Patient Outcomes

Retrieved on: 
Tuesday, April 27, 2021
Professional services, Medical devices, Health, Small business, Surgery, Other Health, Companies, Amersham, GE Healthcare, Magnetic resonance imaging, Radiopharmaceuticals, Economy of the United States, General Electric, Industry economics)

View the full release here: https://www.businesswire.com/news/home/20210427005039/en/\nGE Healthcare CARESCAPE\xe2\x84\xa2 ONE Monitor (Photo: Business Wire)\n\xe2\x80\x9cWe\xe2\x80\x99ve worked closely with GE Healthcare to identify product categories where our combined capabilities best serve our government customers,\xe2\x80\x9d said Wendy Tommelleo , Executive Vice President of First Nation Group.

Key Points: 
  • View the full release here: https://www.businesswire.com/news/home/20210427005039/en/\nGE Healthcare CARESCAPE\xe2\x84\xa2 ONE Monitor (Photo: Business Wire)\n\xe2\x80\x9cWe\xe2\x80\x99ve worked closely with GE Healthcare to identify product categories where our combined capabilities best serve our government customers,\xe2\x80\x9d said Wendy Tommelleo , Executive Vice President of First Nation Group.
  • From anesthesia delivery systems to ventilators and patient monitors, GE Healthcare offers medical devices that help clinicians support patient care throughout the patient journey.
  • Additionally, First Nation Group will offer GE Healthcare anesthesia, monitoring, and respiratory equipment to select customers across the Federal Government sector.\n\xe2\x80\x9cGE Healthcare is proud to work with First Nation Group to further extend our commitment to patient care,\xe2\x80\x9d said GE Healthcare Channel Sales Support Executive Cassandra Farr.
  • \xe2\x80\x9cThis important relationship unites GE Healthcare solutions with the clinical expertise of First Nation Group to positively impact the communities we collectively serve.\xe2\x80\x9d\nGE Healthcare is the $18 billion healthcare business of GE (NYSE: GE).

Fit for the COVID Fight: GE Healthcare Expands Ultrasound Family with New Point of Care System and AI Offering

Retrieved on: 
Tuesday, March 30, 2021
Technology, Biotechnology, Diabetes, Health, Radiology, Other Technology, Research, Medical devices, Infectious diseases, Hospitals, Hardware, Science, Cardiology, Medical Supplies, Classical mechanics, Medical ultrasonography, Companies, Acoustics, Amersham, GE Healthcare, Magnetic resonance imaging, Radiopharmaceuticals, Emergency ultrasound, General Electric, Ultrasound

The Venue Fit is the smallest system in GE Healthcares Venue Family, featuring an easy-to-clean touchscreen, intuitive scanning tools, and a small footprint designed to fit in tight spaces often found in point-of-care settings.

Key Points: 
  • The Venue Fit is the smallest system in GE Healthcares Venue Family, featuring an easy-to-clean touchscreen, intuitive scanning tools, and a small footprint designed to fit in tight spaces often found in point-of-care settings.
  • The new Venue Fit ultrasound system helps meet the needs of providers in tight spaces needing quick imaging insights.
  • This past year weve seen point of care ultrasound take a prominent place at the bedside for clinicians, driven by its intuitive design and AI-powered diagnostic prowess, said Dietmar Seifriedsberger, general manager of Point of Care Ultrasound at GE Healthcare.
  • For information about the Venue Fit, the new software offerings, and to access the Venue Family interactive educational platform visit: https://venue-pocus.gehealthcare.com/
    GE Healthcare is the $18 billion healthcare business of GE (NYSE: GE).

Seasoned Healthcare Executive Michael Raymer Joins Pro-ficiency as CEO

Retrieved on: 
Thursday, March 4, 2021
Amersham, GE Healthcare, Magnetic resonance imaging, Radiopharmaceuticals, Raymer, Puritan Bennett, Medical technology, Medicine, Health care

Raymer joins Pro-ficiency with over 25 years of executive experience in the development of healthcare enterprise software, medical devices, diagnostics, and consumer health products including leadership positions at Perspective Diagnostics, M*Modal, Microsoft, GE Healthcare, and Nellcor Puritan Bennett.

Key Points: 
  • Raymer joins Pro-ficiency with over 25 years of executive experience in the development of healthcare enterprise software, medical devices, diagnostics, and consumer health products including leadership positions at Perspective Diagnostics, M*Modal, Microsoft, GE Healthcare, and Nellcor Puritan Bennett.
  • "Michael is exactly who we need for this next phase of growth at Pro-ficiency," says JoAnne Schaberick, Co-Founder and Chief Awesomeness Officer.
  • As CEO, Raymer is positioned to expedite Pro-ficiency's growth trajectory and position the organization as a leader in the study startup and clinical trials training space.
  • The investment team consists of highly seasoned operational and investment professionals with significant investment experience and deep life science and healthcare expertise.

Corero Network Security Continues to Build upon their "Partner-First" DDoS GTM Strategy

Retrieved on: 
Thursday, February 25, 2021
Microsoft, Software, Operating systems, LinkedIn, Recruitment, Denial-of-service attack, Amersham, Twitter

We are fully committed to increase support, sales and marketing initiatives to amplify global expansion via the channel."

Key Points: 
  • We are fully committed to increase support, sales and marketing initiatives to amplify global expansion via the channel."
  • Corero Network Security plc is a global leader in real-time, high-performance, automatic DDoS cyber defense solutions.
  • Corero's key operational centers are located in Marlborough, Massachusetts, USA and Edinburgh, UK, with the Company's headquartered in Amersham, UK.
  • For more information, visit www.corero.com , and follow us on LinkedIn and Twitter .

Corero Network Security Continues to Build upon their "Partner-First" DDoS GTM Strategy

Retrieved on: 
Thursday, February 25, 2021
Microsoft, Software, Operating systems, LinkedIn, Recruitment, Denial-of-service attack, Amersham, Twitter

We are fully committed to increase support, sales and marketing initiatives to amplify global expansion via the channel."

Key Points: 
  • We are fully committed to increase support, sales and marketing initiatives to amplify global expansion via the channel."
  • Corero Network Security plc is a global leader in real-time, high-performance, automatic DDoS cyber defense solutions.
  • Corero's key operational centers are located in Marlborough, Massachusetts, USA and Edinburgh, UK, with the Company's headquartered in Amersham, UK.
  • For more information, visit www.corero.com , and follow us on LinkedIn and Twitter .